EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study

Y Shi iD, A Sun, C W Chiang, Y Yang, K M Hunold, J Xu, M Russo iD, J Caterino, M T Eadon, L Li, J Su, M Donneyong iD und 1 weitere

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Y Shi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NLM NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Use of three‐drug combinations is increasingly prevalent and associated with an increased risk of adverse drug events ( ADEs ). While real‐world data‐based pharmacovigilance and pharmacoepidemiology studies have derived knowledge on potential adverse three‐drug combinations, the relationship between doses of each drug in three‐drug combination exposure and the risk of ADEs remains unclear.

Methods

We derived matched case–control datasets from US nationwide health insurance claims data for potential ADEs including acute kidney injury, acute myocardial infarction, gastrointestinal bleeding, hypoglycemia, and opioid‐related ADE . We used the conditional logistic regression model to investigate the relationship between the dose of three‐drug combination exposure and the risk of ADE . We used Benjamini and Hochberg's procedure to control the false discovery rate ( FDR ). We explored the relationship between the reduction of drug dose and the risk of ADE .

Results

We identified over 500 potential adverse three‐drug combinations from approximately two million case–control pairs (all odds ratios ≥ 1.3 and FDR < 0.05). For the signals, compared with a high‐dose level of all three drugs, 74% of three‐drug combinations had a lower risk by decreasing the dose of one drug without any drug discontinuation ( p value < 0.05).

Conclusions

Certain three‐drug combinations are associated with an increased risk of ADE . Dose of exposure might be used to evaluate the risk of ADE for a majority of adverse three‐drug combinations. Plain Language Summary Use of three‐drug combinations is increasingly prevalent and associated with an increased risk of adverse drug events (ADEs). We identified potential adverse three‐drug combinations from real‐world data, and revealed the corresponding relationships between doses and risks of ADEs. We find doses might be used to evaluate the risk of ADE for many adverse three‐drug combinations. Additionally, we find risk of many adverse three‐drug combinations might be decreased by reducing the dose of one drug without any drug discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsHumansUnited StatesMiddle AgedMaleCase-Control StudiesFemaleDose-Response Relationship, DrugAgedAdultDatabases, FactualDrug CombinationsInsurance Claim ReviewPharmacovigilancePharmacoepidemiologyYoung AdultAdolescent

Stichwörter der Autor:innen

adverse drug eventsdosedrug combinationpharmacoepidemiologytoxicity

Substanzen

Drug Combinations

Autor:innen und Institutionen

  • Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.
  • Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA.
  • Department of Emergency Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Statistics, The Ohio State University, Columbus, Ohio, USA.
  • Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Y Shi, M Russo, M Donneyong

Förderung

  • NIA NIH HHS
  • NLM NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Shi, Y., Sun, A., Chiang, C. W., Yang, Y., Hunold, K. M., Xu, J., Russo, M., Caterino, J., Eadon, M. T., Li, L., Su, J., Donneyong, M., & Zhang, P. (2025). Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70199

Vancouver

Shi Y, Sun A, Chiang CW, Yang Y, Hunold KM, Xu J, et al. Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70199

BibTeX
@article{Shi2025,
  author = {Shi, Y and Sun, A and Chiang, C W and Yang, Y and Hunold, K M and Xu, J and Russo, M and Caterino, J and Eadon, M T and Li, L and Su, J and Donneyong, M and Zhang, P},
  title = {Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70199}
}
Kostenlos starten →